奶牛中型无绿藻性乳房炎

目前已有12个国家报道无绿藻性奶牛乳房炎,造成严重的经济损失并对公共安全存在潜在的危害.2010年春季,北京地区某奶牛场暴发中型无绿藻引起的临床型乳房炎.从患有临床型乳房炎的10头奶牛的11个乳区分离到8株酵母样微生物,鉴定为中型无绿藻.用16种抗生素药敏纸片进行药敏试验,结果显示中型无绿藻仅对庆大霉素、链霉素和阿米卡星等氨基糖苷类抗生素敏感.同化试验证明该分离株能发酵葡萄糖和丙三醇.本试验在我国首次报道了中型无绿藻能引起奶牛临床型乳房炎.     

Bovine mastitis: an evolving disease

Mastitis remains a major challenge to the worldwide dairy industry despite the widespread implementation of mastitis control strategies. The last forty years have seen a dramatic decrease in clinical mastitis incidence but this has been accompanied by a change in the relative and absolute importance of different pathogens. Escherichia coli and Streptococcus uberis are now the two most common causes of bovine mastitis and are an increasing problem in low somatic cell count herds. This paper reviews the changes in incidence and pattern of mastitis in the UK over the last four decades and discusses some of the possible explanations for these changes. It focuses in particular on apparent changes in the behaviour of E. coli and its ability to cause persistent intramammary infection; which may be as a result of bacterial adaptation or the unmasking of previously unrecognized patterns of pathogenesis. The prospects for novel approaches to mastitis control are discussed, as are the current and future challenges facing the industry.     

Bovine mastitis therapy and why it fails

Treatment of bovine mastitis depends on the cause, the clinical manifestation and the antibiotic susceptibility of the agent. Mastitis therapy is commonly unsuccessful owing to pathological changes that occur in the udder parenchyma as a result of the inflammatory reaction to mastitogenic bacteria, pharmacokinetic properties of antimicrobial mastitis drugs, mastitogenic bacterial and related factors, and poor animal husbandry and veterinary interventions.     

Bovine mastitis caused by Prototheca zopfii: a case study

An outbreak of severe indurative mastitis in newly calved cows, from which Prototheca zopfii was isolated, is described. The refractory nature of this type of mastitis and the ineffectiveness of the presently available intramammary preparations are highlighted.     

Bovine mastitis in Ontario due to Mycoplasma agalactiae subsp. bovis.

Bovine mastitis caused by Mycoplasma agalactiae subsp. bovis was first diagnosed in 16 of 55 cows in an Ontario herd in Feburary 1972. A total of 182 of 598 (30.4%) cows from 33 of 64 (51.5%) farms in widely separated areas of the province were culturally positive. Herd incidence varied from 15 to 40% with one closed herd having an incidence of 61%. Four herds were investigated culturally and serologically by the growth inhibition test for 15 months. In the acute phase the organism was present in the milk in extremely high numbers and could still be isolated from a few cows after eight to 12 months. The sera from 89.5% of the animals with clinical mycoplasma mastitis produced a zone of surface "film" and/or colony inhibition and some cows remained positive for six to 12 months. The disease was experimentally reproduced with a pure culture of the organism isolated from the milk of a cow from one of the herds.     

Bovine mastitis and antibiotic resistance patterns in Selalle smallholder dairy farms, central Ethiopia

A study was conducted to determine the prevalence of mastitis, identify the major bacterial pathogens and test the antimicrobial resistance of milk bacterial isolates in smallholder dairy farms in Selalle area, Ethiopia. A total of 109 smallholder dairy farms comprising 500 crossbred lactating cows were included. The prevalence of clinical mastitis at herd, cow and quarter level was 8.3% (n = 9), 1.8% (n = 9) and 0.51% (n = 10), respectively, while that of sub-clinical mastitis was 54.7%, 22.3% and 10.1%, respectively. The univariate logistic regression showed that among the risk factors considered, presence of teat lesion, stage of lactation and parity number had significant effect on the prevalence of sub-clinical mastitis. However, after multivariate analysis, only presence of teat lesion and stage of lactation had significant effect. The common isolates from the clinical mastitic quarters were St. agalactiae (30%, n = 3) and St. dysgalactiae (30%, n = 3), while from sub-clinical cases were S. aureus (42.6%, n = 83), S. epidermidis (22.1%, n = 43), St. agalactiae (12.8%, n = 25) and St. uberis (10.3%, n = 20). Staphylococcus intermedius and Streptococcus dysgalactiae were the species, which showed high level of susceptibility for most of the antimicrobials tested, while the remaining had varying levels of resistance for almost all the antimicrobials used. Among the antimicrobials employed, erythromycin and sulphonamide showed the lowest proportion of resistant isolates. Considering the possible significant economic losses that could be incurred by both clinical and sub-clinical mastitis, attention should be paid for further detailed investigations including the economic losses and benefits of interventions in the study area.